Valuation: BIOLASE, Inc.

Chart: BIOLASE, Inc.

26/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT
05/03/25	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/02/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/02/25	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/02/25	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/02/25	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/01/25	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/01/25	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/01/25	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/01/25	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/12/24	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/11/24	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/04/24	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/05/23	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/01/23	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/05/22	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/10/25	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/11/24	Biolase: Q3 Earnings Snapshot	AQ
08/11/24	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
01/10/24	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
08/08/24	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	09/09/2025
Steven Sandor COO	Chief Operating Officer	46	05/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	30/09/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	31/08/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	15/08/2021
Martha Somerman BRD	Director/Board Member	-	15/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/09/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	144,501	13.8444%
08/06/23	Jonathan Lord	Free	Chairman	721,154	2.3039%
08/06/23	Kathleen O'Loughlin	Free	Director	502,404	1.6050%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	0.00%	0.00%	-	-	36
CHURCHILL CAPITAL CORP XI	-6.71%	-9.82%	-	-	813M
CENTIEL AG	+14.94%	+6.20%	+343.53%	-66.04%	668M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	645M
CHURCHILL CAPITAL CORP XII	-0.74%	0.00%	-	-	595M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.59%	+0.59%	-	-	602M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	-0.29%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.26%	-0.86%	-	-	569M
CHURCHILL CAPITAL CORP XIII	-0.10%	-0.38%	-	-	507M
Average	+0.74%	-1.72%	+343.53%	-66.04%	554.71M
Weighted average by Cap.	+0.71%	-2.33%	+343.53%	-66.04%